References
Genta Incorporated. Genta Announces 3rd Quarter 2004 Financial Results. Media Release: 9 Nov 2004. Available from: URL: http://www.genta.com
Genta Incorporated. Genta Files New Drug Application for FDA Approval of Genasense(R) Plus Chemotherapy for Patients with Advanced or Refractory Chronic Lymphocytic Leukemia. Media Release: 29 Dec 2005. Available from URL: http://www.genta.com
Genta Incorporated. Genasense(R) New Drug Application Accepted for Review by FDA. Media Release: 1 Mar 2006. Available from URL: http://www.genta.com
Genta Incorporated. Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia. Media Release: 6 Oct 2006. Available from URL: http://www.genta.com
Genta Incorporated. Genta Receives FDA Fast Track Designation for Genasense(TM) In Chronic Lymphocytic Leukemia. Media Release: 30 Jun 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genta receives orphan drug designation for three new cancer indications. Media Release: 4 Sep 2001. Available from URL: http://www.genta.com
Genta Incorporated. Genta receives new fast track designation in U.S. and European orphan drug actions for new cancer indications. Media Release: 20 Sep 2001. Available from URL: http://www.genta.com
Genta Incorporated. Genta Incorporated Announces Third Quarter 2006 Financial Results and Corporate Highlights. Media Release: 7 Nov 2006. Available from URL: http:// www.genta.com
Genta Incorporated. Genasense(R) Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency. Media Release: 01 Feb 2006. Available from URL: http://www.genta.com
Genta Incorporated. Genta Completes Marketing Authorization Application to EMEA for Approval of Genasense(R) plus Chemotherapy for Patients with Advanced Melanoma. Media Release: 3 Jan 2006. Available from URL: http:// www.genta.com
Genta Incorporated. Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma. Media Release: 2 Feb 2007. Available from URL: http://www.genta.com
Genta Incorporated. CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma. Media Release: 27 Apr 2007. Available from URL: http://www.genta.com
Genta Incorporated, Aventis. FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced Melanoma. Media Release: 3 May 2004. Available from URL: http:// www.genta.com
Genta Incorporated. Genta Completes New Drug Application for Approval of Genasense(TM) in Patients with Advanced Malignant Melanoma. Media Release: 9 Dec 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genta Announces 2nd Quarter 2004 Financial Results. Media Release: 3 Aug 2004. Available from URL: http://www.genta.com
Genta Incorporated. Genta announces orphan drug designation from Food and Drug Administration and completes strategic review for its lead compounds, Genasense (TM). Media Release: [2 pages], 7 Aug 2000. Available from URL: http:// www.genta.com
Genta Incorporated. Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma. Media Release: 17 Oct 2006. Available from URL: http:// www.genta.com
Genta Incorporated, Aventis. Genta and Aventis Report Positive Results in Phase 3 Trial of Genasense(TM) Plus Chemotherapy in Patients with Advanced Malignant Melanoma. Media Release: 10 Sep 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genta Reports Fourth Quarter and Year End 2002 Results and Progress. Media Release: 13 Feb 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma. Media Release: 18 Apr 2007. Available from URL: http:// www.genta.com
Genta Incorporated. Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma. Media Release: 29 Nov 2006. Available from URL: http:// www.genta.com
Chi KN, Murray R, Gleave ME, et al. A phase II study of oblimersen sodium (G3139) and docetaxel in patients with metastatic hormone-refractory prostate cancer. 39th Annual Meeting of the American Society of Clinical Oncology: 393 (plus poster) abstr. 1580, 31 May 2003
Genta Incorporated. Genasense(TM) Plus Taxotere(R) Reported Active in Patients with Hormone-Refractory Prostate Cancer at ASCO Meeting. Media Release: 3 Jun 2003. Available from URL: http://www.genta.com
Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137–1141, 19 Apr 1997
Raynaud F, Foster L, Judson I. Clinical pharmacokinetics of G3139, oligonucleotide antisense to bcl-2. 89th Annual Meeting of the American Association for Cancer Research: 521, 28 Mar 1998
Genta Incorporated. Investigator reports on results on Genta’s antisense product G3139 in malignant melanoma trial presentation at the Cold Spring Harbor Conference on Prorogrammed Cell Death. Media Release: [3 pages], 1 Oct 1999. Available from URL: http://www.genta.com
Cunningham D, Webb A, Waters JS. Preliminary results of a phase I trial of antisense to Bcl-2 in non Hodgkin’s lymphoma. Eighth International Congress on Anti-Cancer Treatment: 118, 3 Feb 1998
Cotter FE. BCL-2 antisense therapy: in vitro, in vivo and human trial experiences in haematological malignancies. Naunyn-Schmiedeberg’s Archives of Pharmacology 358 (Suppl. 1): 205, No. 1, 1998
Waters JS, Webb A, Cunningham D. Results of a phase I clinical trial of BCL-2 antisense molecule G3139 (GENTA) in patients with non-Hodgkin’s lymphoma. 35th Annual Meeting of the American Society of Clinical Oncology 18: 4, 15 May 1999
Jansen B, Wacheck V, Heere-Ress E. A phase I/II study with dacarbazine and bcl-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma. 35th Annual Meeting of the American Society of Clinical Oncology 18: 531, 15 May 1999
Morris MJ, Tong WP, Cordon-Cordo C, et al. A phase I trial of BCL2 antisense drug G3139 (Genta, Inc.) delivered by contin- uous intravenous infusion alone and in combination with weekly paclitaxel. Clinical Cancer Research 5 (Suppl.): 3732–3733, Nov 1999
Tolcher AW, Kuhn J, Basler J, et al. A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and docetaxel in patients with hormone-refractory prostate cancer. 11th NCI-EORTC-AACR symposium on new drugs in cancer therapy: 148 (plus poster), 7 Nov 2000
Genta Incorporated. Investigators report results of Genasense (TM) studies in chronic lymphocytic leukemia. Media Release: [2 pages], 10 Dec 2001. Available from URL: http:// www.genta.com
Morris MJ, Tong WP, Cordon-Cardo C, et al. BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer. European Journal of Cancer 37 (Suppl. 6): 218–219 (plus poster), Oct 2001
Marcucci G, Bloomfield CD, Balcerzak SP, et al. Biologic activity of G3139 (Genasense TM), a BCL-2 antisense, refractory or relapsed acute leukemia. 37th Annual Meeting of the American Society of Clinical Oncology 20: 288 (plus oral presentation), Part 1, 12 May 2001
Genta Incorporated. Genasense(TM) Combination With Chemotherapy Reported Useful in Newly Diagnosed Patients With Small Cell Lung Cancer. Media Release: 3 Jun 2003. Available from URL: http://www.genta.com
Genta Incorporated. Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology. Media Release: 15 Sep 2006. Available from URL: http:// www.genta.com
Genta Incorporated. Genasense(R) Phase 3 Results in Malignant Melanoma Updated at ASCO. Media Release: 16 May 2005. Available from URL: http://www.genta.com
Chanan-Khan AA, Niesvizky R, Hohl RJ, et al. Randomized multicenter phase 3 trial of high-dose dexamethasone with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma. Blood 104: 413 (plus poster) abstr. 1477, No. 11, Part 1, 16 Nov 2004
Genta Incorporated. Phase 3 Results of Genasense(R) Plus Dexamethasone in Patients With Advanced Multiple Myeloma Presented at ASH Meeting. Media Release: 4 Dec 2004. Available from URL: http://www.genta.com
Genta Incorporated. Genasense(R) Significantly Increases Major Responses in Patients with Advanced Chronic Lymphocytic Leukemia. Media Release: 6 Dec 2004. Available from URL: http://www.genta.com
Genta Incorporated. Phase 2 Results of Genasense(R) Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference. Media Release: 23 Feb 2007. Available from URL: http://www.genta.com
Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101: 425–432, 15 Jan 2003
Genta Incorporated. Investigators report Genta’s antisense drug combined with standard chemotherapy cures human lymphomas and breast cancers in mouse models. Media Release: [3 pages], 19 Apr 1999. Available from URL: http:// www.frbinc.com
Genta Incorporated. Major progress in aggressive cancer type reported for Genta’a lead antisense drug. Media Release: [1 page], 14 Apr 2000. Available from URL: http:// www.genta.com
Genta Incorporated. New results from Genta’s Gensynergy TM program show marked enhancement of cisplatin activity by Genasense TM in stomach cancer. Media Release: [2 pages], 12 Oct 2001. Available from URL: http://www.genta.com
Genta Incorporated. New studies show Genasense (TM) potentiates anticancer actions of Taxotere (R) and Rituxan (R). Media Release: 8 Apr 2002. Available from URL: http:// www.genta.com
Genta Incorporated. New Experimental Results Show Genasense(R) Enhances Radiation Therapy in Colon Cancer. Media Release: 19 Oct 2005. Available from URL: http:// www.genta.com
Brown BD, Paine-Murrieta GD, Von Hoff DD, et al. Intermittent dosing of Bcl-2 antisense (Genasense) increases anticancer activity as a single-agent and in combination with cytotoxic chemotherapy. 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: 65–66 (plus poster) abstr. A39, 14 Nov 2005
Genta Incorporated. Preclinical Results Show Genasense(TM) Synergizes with Campath(R) in Chronic Lymphocytic Leukemia. Media Release: 4 Jun 2003. Available from URL: http:// www.genta.com
Cotter FE, Auer R, Corbo M, et al. Oblimersen sodium (G3139) sensitizes malignant B-cells to alemtuzumab induced apoptosis. 39th Annual Meeting of the American Society of Clinical Oncology: 227, 31 May 2003
Genta Incorporated. New data reaffirm Genta’s molecular target as critical factor for enhancing anticancer treatment. Media Release: [3 pages], 27 Mar 2001. Available from URL: http:// www.genta.com
Genta Incorporated. Genasense (TM) shown to be highly synergistic with additional anticancer drugs at European Hematology Meeting. Media Release: [2 pages], 25 Jun 2001. Available from URL: http://www.genta.com
Genta Incorporated. Single-Agent Activity of Genta’s Lead Anticancer Compound, Genasense(TM), Reported in Nasopharyngeal Carcinoma. Media Release: 9 Apr 2003. Available from URL: http://www.genta.com
Genta Incorporated. Preclinical Studies Demonstrate Activity of Genasense(TM) Alone and in Combination with Radiation Therapy. Media Release: 19 Nov 2003. Available from URL: http://www.genta.com.
Genta Incorporated. Genta Incorporated Announces Fourth Quarter and Year End 2004 Results. Media Release: 17 Feb 2005. Available from URL: http://www.genta.com
Genta Incorporated. New Analyses from Phase 3 Trial in CLL Identify Relapsed Patients who Maximally Benefit from Genasense(R) Treatment. Media Release: 8 Nov 2006. Available from URL: http://www.genta.com
Genta Incorporated. Updated Analysis from Phase 3 Trial of Genasense(R) in CLL Shows Significant Increase in Duration of Major Responses. Media Release: 13 May 2005. Available from URL: http://www.genta.com
Genta Incorporated. Data from Phase 3 Trial of Genasense(R) Confirm Extended Durability of Remission and Benefit in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Media Release: 19 Sep 2005. Available from URL: http://www.genta.com
Genta Incorporated. Single-Agent Activity of Genta’s Lead Anticancer Compound, Genasense(TM), Reported in Patients with Advanced Chronic Lymphocytic Leukemia. Media Release: 9 Dec 2002. Available from URL: http:// www.genta.com
Jansen B, Wacheck V, Heere-Ress E, et al. Systemic treatment with bcl-2 antisense down-regulates tumor content of bcl-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine. 91st Annual Meeting of the American Association for Cancer Research: late-breaking abstracts: 7, 1 Apr 2000
Genta Incorporated. Genta’s lead antisense drug reported active in malignant melanoma new data on antisense mechanism and clinical response reported in leading journal. Media Release: [3 pages], 17 Nov 2000. Available from URL: http:// www.genta.com
Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728–1733, 18 Nov 2000
Genta Incorporated. Genta Announces Updated Results From Its Phase 3 Trial of Genasense(TM) for Advanced Melanoma. Media Release: 7 Jun 2004. Available from URL: http:// www.genta.com
Genta Incorporated. Clinical Study Results Show Genasense(TM) May Delay Progression in Patients With Aggressive Non-Hodgkin’s Lymphoma. Media Release: 2 Jun 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genasense(TM) plus Rituxan(R) Reported Active in Non-Hodgkin’s Lymphoma. Media Release: 8 Dec 2003. Available from URL: http://www.genta.com
Genta Incorporated. Clinical Activity of Genasense in Patients with Refractory Myeloma Highlighted in Multiple Presentations at International Scientific Meeting. Media Release: 27 May 2003. Available from URL: http://www.genta.com
Genta Incorporated. Genasense(TM) Reported Active in Combination with Chemotherapy in Multiple Myeloma. Media Release: 9 Dec 2003. Available from URL: http:// www.genta.com
Genta Incorporated. Genasense(R) plus Rituximab Reported Active in Patients with Relapsed Non-Hodgkin’s Lymphoma. Media Release: 13 Jun 2005. Available from URL: http:// www.genta.com
Genta Incorporated. Pilot Clinical Study of Genasense(R) Plus Rituxan(R) and Fludarabine Shows Activity in Chronic Lymphocytic Leukemia. Media Release: 12 Dec 2005. Available from URL: http://www.genta.com
Genta Inc. Genta gets early positive results of Genasense clinical trial. Media Release: [3 pages], 13 Nov 2000. Available from URL: http://www.genta.com
Cancer Therapy & Research Center. G3139 (Genasense (TM)) in combination with docetaxel (Taxotere (Rm)) shows promise in advanced prostate cancer. Media Release: [4 pages], 12 May 2001
Rights and permissions
About this article
Cite this article
Oblimersen. Drugs R D 8, 321–334 (2007). https://doi.org/10.2165/00126839-200708050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200708050-00006